GSK Malarone safety profile
Executive Summary
Safety data comparing GlaxoSmithKline's Malarone (atovaquone/proguanil) to older antimalarials approved for Malarone label, GSK said Aug. 22. In clinical studies, patients taking Malarone had fewer neuropsychiatric side effects than Roche's Lariam (mefloquine) (14% vs. 29%) and fewer gastrointestinal events than patients receiving chloroquine/proguanil (12% vs. 20%)...
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.